Related Experiment Videos
Pathogenesis of dialysis-related amyloidosis
Abstract:
Beta 2-microglobulin has been demonstrated to be a major constituent of amyloid fibrils in dialysis-related amyloidosis. However, the molecular pathogenesis of this complication remains unknown. Several lines of evidence suggest that beta 2-microglobulin is not an innocent bystander, but plays an active role in the development of dialysis-related amyloidosis. The evidence remains inconclusive, however, as to whether it is intact or modified beta 2-microglobulin which is amyloidogenic and contributes to bone and joint destruction. Recent biochemical and immunohistological studies have revealed a new modification of beta 2-microglobulin in amyloid fibrils, the advanced glycation end products formed nonenzymatically between aldoses and proteins. Further study has suggested that the interaction of advanced glycation end product-modified beta 2-microglobulin with monocytes/macrophages gives a plausible, albeit incomplete, explanation for the mechanism of bone and joint destruction in dialysis-related amyloidosis. This review focuses on new aspects of the pathogenesis of dialysis-related amyloidosis.
Insights
Dialysis-related amyloidosis involves beta 2-microglobulin, a protein that may be modified by advanced glycation end products. This modification offers insights into bone and joint destruction in dialysis patients.
Area of Science:
- Nephrology
- Biochemistry
- Immunology
Background:
- Beta 2-microglobulin is a major component of amyloid fibrils in dialysis-related amyloidosis.
- The exact molecular pathogenesis of this complication is not fully understood.
- Evidence suggests beta 2-microglobulin plays an active role in dialysis-related amyloidosis development.
Purpose of the Study:
- To review new aspects of the pathogenesis of dialysis-related amyloidosis.
- To explore the role of modified beta 2-microglobulin in the disease.
- To investigate the mechanism of bone and joint destruction.
Main Methods:
- Biochemical studies
- Immunohistological studies
- Review of recent literature
Main Results:
- Advanced glycation end products (AGEs) are a newly identified modification of beta 2-microglobulin in amyloid fibrils.
- AGE-modified beta 2-microglobulin interacting with monocytes/macrophages provides a potential mechanism for bone and joint destruction.
- The role of intact versus modified beta 2-microglobulin in amyloidogenesis remains under investigation.
Conclusions:
- Advanced glycation end product modification of beta 2-microglobulin is a significant factor in dialysis-related amyloidosis.
- The interaction of AGE-modified beta 2-microglobulin with immune cells offers a plausible explanation for tissue damage.
- Further research is needed to fully elucidate the complex pathogenesis of dialysis-related amyloidosis.